Understand the source comparison
Best Research Peptides for Diabetic Neuropathy Research: Mechanism Comparison
BPC-157 VEGF upregulation, angiogenesis, nitric oxide signaling 34% increase in nerve conduction velocity in diabetic rat models (12 weeks) Subcutaneous injection Strongest vascular repair evidence; most studied in peripheral nerve injury models TB-500 Actin r
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, angiogenesis, nitric oxide signaling
- 34% increase in nerve conduction velocity in diabetic rat models (12 weeks)
- Subcutaneous injection
- Strongest vascular repair evidence; most studied in peripheral nerve injury models
- TB-500
- Actin regulation, axonal sprouting, Schwann cell migration
- 41% increase in axonal sprouting density vs controls (8 weeks)
- Mechanistically complementary to BPC-157; supports structural nerve regeneration
- Semax
- BDNF upregulation, TrkB receptor activation, antioxidant activity
- 2.8-fold increase in sciatic nerve BDNF; 38% reduction in oxidative stress markers
- Intranasal administration
- Best evidence for trophic factor-mediated neuroprotection; crosses blood-nerve barrier
- MOTS-c
- AMPK activation, mitochondrial biogenesis, ATP restoration
- 47% increase in nerve ATP content; improved mitochondrial membrane potential
- Addresses bioenergetic deficits; may enhance efficacy of other neuroregenerative peptides
- Cerebrolysin
- Mixed NGF-like and BDNF-like activity
- Modest improvements in nerve conduction studies (mixed-etiology neuropathy trials)
- Intravenous infusion
- Evidence less diabetes-specific; proprietary formulation limits mechanistic clarity